UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: (Date of earliest event reported): August 6, 2019

Calyxt, Inc. (Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

Common Stock, par value \$0.0001 per share

001-38161 (Commission File Number)

27-1967997 (IRS Employer **Identification No.)**

The NASDAQ Global Market

2800 Mount Ridge Road Roseville, MN 55113-1127 (Address and zip code of principal executive offices)

(651) 683-2807 (Registrant's telephone number, including area code)					
(Forn	Not Applicable ner name or former address, if changed since last r	report)			
Check the appropriate box below if the Form 8-K fil rovisions:	ling is intended to simultaneously satisfy the filing obl	ligation of the registrant under any of the following			
☐ Written communications pursuant to Rule 425	under the Securities Act (17 CFR 230.425)				
Soliciting material pursuant to Rule 14a-12 un	der the Exchange Act (17 CFR 240.14a-12)				
Pre-commencement communications pursuant	to Rule 14d-2(b) under the Exchange Act (17 CFR 24	40.14d-2(b))			
Pre-commencement communications pursuant	to Rule 13e-4(c) under the Exchange Act (17 CFR 24	40.13e-4(c))			
ndicate by check mark whether the registrant is an ear Rule 12b-2 of the Securities Exchange Act of 193	emerging growth company as defined in Rule 405 of t 34 (§240.12b-2 of this chapter).	the Securities Act of 1933 (§230.405 of this chapter)			
		Emerging growth company \boxtimes			
f an emerging growth company, indicate by check nevised financial accounting standards provided purs	mark if the registrant has elected not to use the extended suant to Section 13(a) of the Exchange Act \Box	ed transition period for complying with any new or			
securities registered pursuant to Section 12(b) of the	e Act:				
Title of each class	Trading Symbol(s)	Name of exchange on which registered			

CLXT

Item 2.02. Results of Operations and Financial Condition

On August 6, 2019, Calyxt, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

d. Exhibits

Exhibit

Number Description

99.1 Press Release of Calyxt, Inc. dated August 6, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Calyxt, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 6, 2019

CALYXT, INC

By: /s/ James A. Blome

Name: James A. Blome Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit

Number Description

99.1 Press Release of Calyxt, Inc. dated August 6, 2019

Calyxt Reports 2nd Quarter Financial Results

Calyno™ High Oleic Soybean Oil and High Oleic Soybean Meal customers increase to nearly 20, which includes Sysco
Signed agreement with Landus Cooperative, providing crushing capacity and High Oleic Soybean Meal distribution
Crushed more than 200,000 bushels of High Oleic Soybeans in July, and sold out of resulting High Oleic Soybean Meal
2018 grain purchases nearly complete as of late July 2019

2019 planted acres exceed 36,000 acres

2020 acreage target remains at 100,000 contracted acres

Cash, cash equivalents and restricted cash of \$77.9M

ROSEVILLE, Minn.--(BUSINESS WIRE)--August 6, 2019--Calyxt, Inc. (NASDAQ: CLXT), a healthy food ingredients company, today announced its results for the second quarter ended June 30, 2019.

Investor Call Details

Calyxt will host an investor call on August 7, 2019 at 8:30 a.m. Eastern Time – 7:30 a.m. Central Time to discuss its financial results and provide a general business update.

US & Canada only: +1 (877) 407-9747 International: +1 (412) 902-0044

In addition, a replay of the call will be available for one month following the conference by calling +1 (877) 660-6853 (Toll Free US & Canada); +1 (201) 612-7415 (Toll Free International).

The archived webcast of this event may be accessed through the Calyxt website, using passcode 13673206.

"We are excited by our accomplishments in the second quarter, as we continued to deliver on key operating milestones and progress on the commercial launch of our first product. We have increased our customer base to nearly 20. We are thrilled to have Landus, one of the world's leading agricultural cooperatives and soybean processors, as a crusher and distributer of our High Oleic Soybean Meal. We have also nearly completed the purchase of all stored grain from our growers," said Jim Blome, CEO of Calyxt. "I would also like to highlight the addition of Travis Frey, Ph.D. as our Chief Technology Officer – with Travis we continue to build our leadership team in strategic areas as he advances our technical capabilities and platform. In closing, the first half of 2019 experienced the impact of severe weather resulting in record numbers of prevent plant acres. The impact was felt across the Plains states, and nowhere more than in South Dakota, our primary growing region. Nevertheless, our planted acres were slightly more than 36,000 acres, doubling the acres planted in 2018 and consistent with our original plans for 2019."

High Oleic Soybean

- Continued revenue scale up of Calyno High Oleic Soybean Oil.
 - We are now selling our oil through Sysco, the world's largest foodservice distributor. Our oil is selling in Foodservice at prices consistent with other premium oils. We continue to pursue customers in both the foodservice and food manufacturing segments. Calyno oil performance continues to impress with 3x fry life and less varnish compared to commodity oils, as well as a neutral taste and zero grams of trans fats per serving.
- **Agreement with Landus Cooperative.** We also continued to accelerate our first-mover advantage by expanding our supply chain further through our agreement with Landus Cooperative, one of the world's leading agricultural cooperatives and soybean processors, as a crusher and distributer of our High Oleic Soybean Meal.
- Largest crush in our history. In the month of July, we crushed over 200,000 bushels of our High Oleic Soybeans, the largest crush in Calyxt history. We have subsequently sold out of High Oleic Soybean Meal, and as a result July 2019 will be our best revenue month to date.
- **Prior year grain purchases nearly complete.** As of late July 2019, we had purchased more than 75% of all 2018 Calyxt High Oleic Soybean grain produced by our contracted growers. Purchasing 2018 contracted grain helps us prime our supply chain, validate our identity-preserved supply chain, and further the confidence our valued growers have in Calyxt and our model.
- Planted acres for 2019 were slightly more than 36,000 acres, consistent with our initial expectations for the year. This amount was double what we planted in 2018.
- We reiterate our 2020 guidance of at least 100,000 contracted acres. We expect to launch 2-4 new varieties of soybeans in 2020 and work to increase penetration with existing growers and expand geographically out from our current base. We have also launched our acreage acquisition plan for 2020.

Financial Highlights

- **Revenues** were \$408,000 for the three months ended June 30, 2019, the majority of which were from sales of meal.
- **R&D expenses** were \$2.7 million for the three months ended June 30, 2019 compared to \$3.2 million for the three months ended June 30, 2018. The decrease was due to a \$0.8 million decrease in non-cash stock compensation expense partially offset by an increase in cash expenses associated with additional staff.
- **SG&A expenses** were \$6.4 million for the three months ended June 30, 2019 compared to \$4.0 million for the three months ended June 30, 2018. The increase was due to the addition of personnel to support the commercialization of our High Oleic Soybean products in sales and supply chain and an increase in non-cash stock compensation expense of \$0.8 million.
- **Cash, cash equivalents and restricted cash** were \$77.9 million at June 30, 2019. We are continuing to actively manage the use of cash and expect to have sufficient cash to fund the business into early 2021.

 Our cash spend for the remainder of 2019 is estimated at between \$3 million and \$3.25 million per month and will be

focused in these areas:

- Supporting our product pipeline, including development of additional varieties and traits for soybeans, wheat and alfalfa, as well as continuing to build a strong intellectual property portfolio;
- Continuing to drive the commercialization of our High Oleic Soybean products including our Calyno oil and High Oleic Soybean Meal, which includes spending for sales and marketing support, product samples, and costs associated with agricultural activities including seed production, product samples, grain purchases, and processing and distribution;
- Strengthening our organization to scale to the needs of our customer base and grower partners, including hiring talented personnel and further developing our IT systems as we continue to scale and separate our infrastructure from Cellectis.
- **Loss from operations** was \$9.4 million for the three months ended June 30, 2019 compared to \$7.6 million for the three months ended June 30, 2018.
- **Net cash used in operating activities** was \$15.9 million for the six months ended June 30, 2019, compared to \$8.8 million for the six months ended June 30, 2018.

Corporate Update

- **Travis Frey, Ph.D., Chief Technology Officer.** Travis joined in May and brings his extensive knowledge in plant biology and biotechnology to a newly created position at Calyxt. As CTO, Travis is responsible for leading the R&D team, and propelling product development and our pipeline of healthy food ingredients.
- **Trina Lundblad, Communications Director.** Trina joined in June and leads our efforts related to communicating company initiatives and strategy across a variety of external and internal channels. Prior to joining Calyxt, Trina oversaw marketing communications for Ingredion's North American business with similar roles previously held at Nilfisk and Select Comfort.
- **Paul Weier, Director of Information Technology**. Paul joined in July and is responsible for managing our IT infrastructure. Prior to joining Calyxt, Paul held the role as Senior Director of Technical Operations at LAKANA.

About Calyxt

Calyxt is committed to making the food you love a healthier choice. The care we take extends beyond nutritional value. We partner with farmers and food companies to deliver traceable plant-based products developed to be healthier and more sustainable than their conventional counterparts. We use cutting edge plant breeding techniques to develop products that help improve diets by reducing bad fats, allergens and toxins. Today oil from our high oleic soybean plants has lower saturated fats than commodity soybean oil. We are also developing high fiber wheat designed to provide an excellent source of daily fiber when incorporated into wheat-based foods. We continuously pursue innovation to deliver good food that is good for you.

Calyxt®, Calyno™ and the corporate logo are trademarks owned by Calyxt, Inc.

Calyxt is located in Roseville, MN, and is listed on the Nasdaq market (ticker: CLXT). For further information please visit our website at www.calyxt.com.

Calyxt Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including those factors discussed under the caption entitled "Risk Factors" in our Annual Report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by applicable laws.

CALYXT, INC. BALANCE SHEETS

(In Thousands, Except Par Value and Share Amounts)

		une 30, 2019 naudited)	Dece	ember 31, 2018
Assets				
Current assets:				
Cash and cash equivalents	\$	76,434	\$	93,794
Restricted cash		381		381
Trade accounts receivable		810		-
Due from related parties		78		46
Inventory		111		-
Prepaid expenses and other current assets		1,470		1,301
Total current assets		79,284		95,522
Non-current restricted cash		1,128		1,113
Land, buildings, and equipment		22,480		21,850
Other non-current assets		684		306
Total assets	\$	103,576	\$	118,791
Liabilities and stockholders' equity				
Current liabilities:				
Accounts payable	\$	395	\$	818
Accrued expenses		1,993		2,007
Accrued compensation and benefits		1,238		1,305
Due to related parties		781		1,905
Current portion of financing lease obligations		308		258
Other current liabilities		253		711
Total current liabilities		4,968		7,004
Financing lease obligations		18,259		18,227
Other non-current liabilities		159		163
Total liabilities		23,386		25,394
Stockholders' equity:		-		
Common stock, \$0.0001 par value; 275,000,000 shares authorized; 32,918,599 shares issued and 32,859,700 shares outstanding as of June 30, 2019 and 32,664,429 shares issued and 32,648,893 shares outstanding as of December 31, 2018		3		3
Additional paid-in capital		180,237		176,069
Common stock in treasury, at cost; 58,899 shares as of June 30, 2019, and 15,536 shares as of December 31, 2018		(789)		(230)
Accumulated deficit		(99,223)		(82,445)
Accumulated other comprehensive loss		(38)		-
Total stockholders' equity		80,190		93,397
Total liabilities and stockholders' equity	\$	103,576	\$	118,791

CALYXT, INC. STATEMENTS OF OPERATIONS

(Unaudited and in Thousands Except Shares and Per Share Amounts)

	Three months ended June 30,				
		2019	2018		
Revenue	\$	408	\$	196	
Operating expenses:					
Cost of revenue		303		-	
Research and development		2,738		3,241	
Selling and general and administrative		6,408		4,048	
Management fees and royalties		451		399	
Total operating expenses		9,900		7,688	
Loss from operations		(9,492)		(7,492)	
Interest, net		92		(72)	
Foreign currency transaction loss		(3)		(12)	
Loss before income taxes		(9,403)		(7,576)	
Income taxes		-		-	
Net loss	\$	(9,403)	\$	(7,576)	
Basic and diluted loss per share	\$	(0.29)	\$	(0.25)	
Weighted average shares outstanding - basic and diluted		32,732,988		29,840,827	

CALYXT, INC. STATEMENTS OF OPERATIONS

(Unaudited and in Thousands Except Shares and Per Share Amounts)

	S	Six months ended June 30,				
		2019		2018		
Revenue	\$	566	\$	207		
Operating expenses:						
Cost of revenue		337		-		
Research and development		4,957		4,410		
Selling and general and administrative		11,475		6,603		
Management Fees		812		982		
Total operating expenses		17,581		11,995		
Loss from operations		(17,015)		(11,788)		
Interest, net		264		(140)		
Foreign currency transaction (loss) gain		(27)		(18)		
Loss before income taxes		(16,778)		(11,946)		
Income taxes		-		-		
Net loss	\$	(16,778)	\$	(11,946)		
Basic and diluted loss per share	\$	(0.51)	\$	(0.41)		
Weighted average shares outstanding - basic and diluted		32,704,834		28,851,491		

CALYXT, INC. STATEMENTS OF CASH FLOWS (Unaudited and in Thousands)

Net loss (16,778) (11,946) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 689 371 Stock-based compensation 3,860 2,427 Unrealized foreign exchange gain — 6 Changes in operating assets and liabilities: Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Investing activities (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Financing activities (5,77,06 (665)		Six months ended June 30,					
Net loss (16,778) (11,946) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 689 371 Stock-based compensation 3,860 2,427 Unrealized foreign exchange gain — 6 Changes in operating assets and liabilities: Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Investing activities (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Financing activities (5,77,06 (665)			2019		2018		
Adjustments to reconcile net loss to net cash used in operating activities: 889 371 Depreciation 3,860 2,427 Stock-based compensation — 6 Unrealized foreign exchange gain — 6 Changes in operating assets and liabilities: — 6 Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (15) (8,828) Investing activities (15,870) (8,828) Investing activities (15,870) (8,828) Investing activities (1,319) (498) Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (5) 5,7,06 Porceeds from common stock issuance <th>Operating activities</th> <th></th> <th></th> <th></th> <th></th>	Operating activities						
Depreciation 689 371 Stock-based compensation 3,860 2,427 Unrealized foreign exchange gain — 6 Changes in operating assets and liabilities: — 6 Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Financing activities — (665)	Net loss	\$	(16,778)	\$	(11,946)		
Stock-based compensation 3,860 2,427 Unrealized foreign exchange gain — 6 Changes in operating assets and liabilities: — 6 Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (Adjustments to reconcile net loss to net cash used in operating activities:						
Unrealized foreign exchange gain — 66 Changes in operating assets and liabilities: — 6810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Financing activities (65) Proceeds from common stock issuance — 57,706 Proceeds from common stock issuance — 57,706 Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement </td <td>Depreciation</td> <td></td> <td>689</td> <td></td> <td>371</td>	Depreciation		689		371		
Changes in operating assets and liabilities: (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (1,319) (498) Purchases of land, buildings and equipment (1,319) (498) Financing activities (1,319) (498) Financing activities — (665) Proceeds from common stock issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — <tr< td=""><td>Stock-based compensation</td><td></td><td>3,860</td><td></td><td>2,427</td></tr<>	Stock-based compensation		3,860		2,427		
Trade accounts receivable (810) — Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Forceeds from common stock issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred relat	Unrealized foreign exchange gain		_		6		
Due to/from related parties (1,156) 47 Inventory (111) — Prepaid expenses and other assets (169) (799) Accounts payable (423) 25 Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities (15,870) (8,828) Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities (1,319) (498) Fosts incurred related to the issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — <td>Changes in operating assets and liabilities:</td> <td></td> <td></td> <td></td> <td></td>	Changes in operating assets and liabilities:						
Inventory	Trade accounts receivable		(810)		_		
Prepaid expenses and other assets Accounts payable Accounts payable Accounts payable Accrued expenses (144) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) Other non-current assets (378) Net cash used by operating activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities Financing activities Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Proceeds from sale and leaseback of land, buildings, and equipment Net cash (used) provided by financing activities (156) Saya82 Net decrease in cash, cash equivalents and restricted cash (17,345) A8,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Due to/from related parties		(1,156)		47		
Accounts payable Accrued expenses (14) 275 Accrued compensation and benefits Other accrued liabilities Other non-current assets Other non-current assets (378) Net cash used by operating activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Net cash used by investing activities Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Costs incurred related to shares withheld for net share settlement Net cash (used) provided by financing activities (17,345) Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Inventory		(111)		_		
Accrued expenses (14) 275 Accrued compensation and benefits (67) (318) Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities Costs incurred related to the issuance of stock — (665) Proceeds from common stock issuance Payments for financing lease obligations (122) — Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Prepaid expenses and other assets		(169)		(799)		
Accrued compensation and benefits Other accrued liabilities Other non-current assets Other non-current assets Other non-current assets Net cash used by operating activities Purchases of land, buildings and equipment Other cash used by investing activities Purchases of land, buildings and equipment Other cash used by investing activities Financing activities Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Costs incurred related to shares withheld for net share settlement Net cash (used) provided by financing activities Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Accounts payable		(423)		25		
Other accrued liabilities (513) 1,084 Other non-current assets (378) — Net cash used by operating activities (15,870) (8,828) Investing activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities Costs incurred related to the issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Accrued expenses		(14)		275		
Other non-current assets Net cash used by operating activities Purchases of land, buildings and equipment Net cash used by investing activities Purchases of land, buildings and equipment Net cash used by investing activities Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Proceeds from sale and leaseback of land, buildings, and equipment Net cash (used) provided by financing activities Net decrease in cash, cash equivalents and restricted cash — beginning of period 95,288 56,664	Accrued compensation and benefits		(67)		(318)		
Net cash used by operating activities(15,870)(8,828)Investing activities(1,319)(498)Purchases of land, buildings and equipment(1,319)(498)Net cash used by investing activities(1,319)(498)Financing activities—(665)Costs incurred related to the issuance of stock—57,706Payments for financing lease obligations(122)—Proceeds from the exercise of stock options3081,241Costs incurred related to shares withheld for net share settlement(559)—Proceeds from sale and leaseback of land, buildings, and equipment217—Net cash (used) provided by financing activities(156)58,282Net decrease in cash, cash equivalents and restricted cash(17,345)48,956Cash, cash equivalents and restricted cash — beginning of period95,28856,664	Other accrued liabilities		(513)		1,084		
Investing activities Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities Costs incurred related to the issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash — beginning of period 95,288 56,664	Other non-current assets		(378)		_		
Purchases of land, buildings and equipment (1,319) (498) Net cash used by investing activities (1,319) (498) Financing activities Costs incurred related to the issuance of stock — (665) Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash — beginning of period 95,288 56,664	Net cash used by operating activities		(15,870)		(8,828)		
Net cash used by investing activities(1,319)(498)Financing activitiesCosts incurred related to the issuance of stock—(665)Proceeds from common stock issuance—57,706Payments for financing lease obligations(122)—Proceeds from the exercise of stock options3081,241Costs incurred related to shares withheld for net share settlement(559)—Proceeds from sale and leaseback of land, buildings, and equipment217—Net cash (used) provided by financing activities(156)58,282Net decrease in cash, cash equivalents and restricted cash(17,345)48,956Cash, cash equivalents and restricted cash – beginning of period95,28856,664	Investing activities						
Financing activities Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations (122) Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Proceeds from sale and leaseback of land, buildings, and equipment Proceeds from sale and restricted cash Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 95,288	Purchases of land, buildings and equipment		(1,319)		(498)		
Costs incurred related to the issuance of stock Proceeds from common stock issuance Payments for financing lease obligations (122) Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Proceeds from sale and leaseback of land, buildings, and equipment Net cash (used) provided by financing activities (156) Sex.282 Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Net cash used by investing activities		(1,319)		(498)		
Proceeds from common stock issuance — 57,706 Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Financing activities						
Payments for financing lease obligations (122) — Proceeds from the exercise of stock options 308 1,241 Costs incurred related to shares withheld for net share settlement (559) — Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Costs incurred related to the issuance of stock		_		(665)		
Proceeds from the exercise of stock options Costs incurred related to shares withheld for net share settlement Proceeds from sale and leaseback of land, buildings, and equipment Net cash (used) provided by financing activities Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 1,241 (559) — (156) 58,282 1,241 (17,345) 48,956	Proceeds from common stock issuance				57,706		
Costs incurred related to shares withheld for net share settlement (559) Proceeds from sale and leaseback of land, buildings, and equipment 217 Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Payments for financing lease obligations		(122)		_		
Proceeds from sale and leaseback of land, buildings, and equipment 217 — Net cash (used) provided by financing activities (156) 58,282 Net decrease in cash, cash equivalents and restricted cash (17,345) 48,956 Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Proceeds from the exercise of stock options		308		1,241		
Net cash (used) provided by financing activities(156)58,282Net decrease in cash, cash equivalents and restricted cash(17,345)48,956Cash, cash equivalents and restricted cash – beginning of period95,28856,664	Costs incurred related to shares withheld for net share settlement		(559)		_		
Net decrease in cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Proceeds from sale and leaseback of land, buildings, and equipment		217		_		
Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Net cash (used) provided by financing activities		(156)		58,282		
Cash, cash equivalents and restricted cash – beginning of period 95,288 56,664	Net decrease in cash, cash equivalents and restricted cash		(17,345)		48,956		
Cash, cash equivalents and restricted cash – end of period \$ 77,943 \$ 105,620	Cash, cash equivalents and restricted cash – beginning of period		95,288		56,664		
	Cash, cash equivalents and restricted cash – end of period	\$	77,943	\$	105,620		

Contacts

Investor Relations:

Simon Harnest, VP Corporate Strategy and Finance

Phone: +1 (646) 385-9008

email: simon.harnest@calyxt.com

Bill Koschak, Chief Financial Officer

Phone: + (651)-401-4401

Email: bill.koschak@calyxt.com

Media:

Trina Lundblad, Director of Communications

Phone: +1 (612) 790-0514 email: media@calyxt.com